Growth hormone (GH) is registered for children with Turner syndrome (T
S) in several countries. Improving the final heights (FH) is certainly
the most worthy goal of therapy, but evaluation of treatment effect i
s complicated by methodological difficulties. Several series of FH res
ults have now been published, with estimated benefits ranging from 0-9
.3 cm, as compared to predicted height before treatment. The majority
of studies report height gains of less than 5 cm, but in these studies
, GH was started at a relatively late age and used at low doses. Sever
al approaches can be utilized to improve FH results in TS, including e
arly initiation of GH therapy, increased or optimized GH dose regimens
, or optimization of sexual steroid utilization.